{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Eupraxia Pharmaceuticals Inc."},"Symbol":{"label":"Symbol","value":"EPRX"},"Address":{"label":"Address","value":"204 - 2590 CADBORO BAY ROAD, VICTORIA, British Columbia, Canada"},"Phone":{"label":"Phone","value":"+1 250 590-3968"},"Industry":{"label":"Industry","value":"Pharmaceuticals and Biotechnology"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product candidates address therapeutic areas with a high unmet medical need and strive to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. Its lead product candidate, EP-104IAR, is in development for the treatment of pain due to osteoarthritis of the knee. In addition, it is developing a pipeline of earlier-stage long-acting formulations."},"CompanyUrl":{"label":"Company Url","value":"www.eupraxiapharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Amanda Malone","title":"Chief Operating & Scientific Officer"},{"name":"James A. Helliwell","title":"Chief Executive Officer & Director"},{"name":"Mark M. Kowalski","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}